Back to top

Has GlaxoSmithKline plc (GSK) Outpaced Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has GlaxoSmithKline plc (GSK - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.

GlaxoSmithKline plc is one of 845 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GSK is currently sporting a Zacks Rank of #2 (Buy).

Over the past 90 days, the Zacks Consensus Estimate for GSK's full-year earnings has moved 1.75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, GSK has moved about 15.28% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.45%. This means that GlaxoSmithKline plc is outperforming the sector as a whole this year.

Looking more specifically, GSK belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #67 in the Zacks Industry Rank. On average, this group has gained an average of 9.85% so far this year, meaning that GSK is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track GSK. The stock will be looking to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


GlaxoSmithKline plc (GSK) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in